Pacific Biosciences is expected to report Q3 2026 revenue of $39.31 million and a consensus EPS loss of $0.13, with its current stock price of $2.61 trading above the $2.29 analyst price target.
Investors are primarily focused on whether management can maintain full-year 2026 guidance after three consecutive downward revisions earlier this year. This report serves as a critical test for new CEO Mark Van Oene following the leadership transition and the launch of the SPARCnext chemistry.
Analysts are looking for sequential growth in Revio system placements and signs of stabilizing demand in the clinical genomics market to validate the company's path toward cash flow breakeven by 2028.